| Reuben Guy Hudson, MD FAAP | |
|
1101 Madison St Ste 800, Swedish Pediatric Specialist Clinic, Seattle, WA 98104-1306 | |
| (206) 215-2700 | |
| (206) 215-2702 |
| Full Name | Reuben Guy Hudson |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Location | 1101 Madison St Ste 800, Seattle, Washington |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1710995295 | NPI | - | NPPES |
| 8425738 | Medicaid | WA | |
| 213391 | Medicaid | OR |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | MD25800 (Oregon) | Primary |
| 208800000X | Urology | MD00048852 (Washington) | Secondary |
| Entity Name | Swedish Health Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689612954 PECOS PAC ID: 0244138196 Enrollment ID: O20031230000187 |
News Archive
Accelerator Corporation, a privately held, venture capital backed biotechnology investment and development company, announced today the Series A Preferred Stock financing of Acylin Therapeutics, Inc. This is the eleventh company backed by Accelerator and its first investment in intellectual property developed by either Johns Hopkins University School of Medicine or The Wistar Institute, the co-owners of the underlying technology.
Every $1 invested in mobile healthcare for the medically disenfranchised saves $36 in combined emergency department costs avoided and value of life years saved.
A recent FDA approval supported by Stand Up To Cancer research provides a new treatment option for patients with an aggressive form of prostate cancer.
Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Green Cross Corporation, a leading company in the development, manufacturing, and commercialization of viral vaccines and other biological products, today reported positive clinical data from a Phase 2 trial evaluating JX-594 for liver cancer which was conducted in South Korea.
The link between autism and disrupted brain development is an essential part of the puzzle of the disease, and is largely unknown. However, thanks to funding from the Simons Foundation Autism Research Initiative, George Washington University researcher Anthony-Samuel LaMantia, Ph.D. may be able to offer truly integrative and in-depth answers to these key questions in the field of autism research.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Reuben Guy Hudson, MD FAAP Po Box 84026, Seattle, WA 98124-8426 Ph: (206) 320-4476 | Reuben Guy Hudson, MD FAAP 1101 Madison St Ste 800, Swedish Pediatric Specialist Clinic, Seattle, WA 98104-1306 Ph: (206) 215-2700 |
News Archive
Accelerator Corporation, a privately held, venture capital backed biotechnology investment and development company, announced today the Series A Preferred Stock financing of Acylin Therapeutics, Inc. This is the eleventh company backed by Accelerator and its first investment in intellectual property developed by either Johns Hopkins University School of Medicine or The Wistar Institute, the co-owners of the underlying technology.
Every $1 invested in mobile healthcare for the medically disenfranchised saves $36 in combined emergency department costs avoided and value of life years saved.
A recent FDA approval supported by Stand Up To Cancer research provides a new treatment option for patients with an aggressive form of prostate cancer.
Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Green Cross Corporation, a leading company in the development, manufacturing, and commercialization of viral vaccines and other biological products, today reported positive clinical data from a Phase 2 trial evaluating JX-594 for liver cancer which was conducted in South Korea.
The link between autism and disrupted brain development is an essential part of the puzzle of the disease, and is largely unknown. However, thanks to funding from the Simons Foundation Autism Research Initiative, George Washington University researcher Anthony-Samuel LaMantia, Ph.D. may be able to offer truly integrative and in-depth answers to these key questions in the field of autism research.
› Verified 2 days ago
Dr. Sandra Jane Hadjinian, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 1959 Ne Pacific St., Seattle, WA 98195 Phone: 206-520-5000 | |
Dr. Steven Han, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 515 Minor Ave, Suite 200, Seattle, WA 98104 Phone: 206-215-2580 Fax: 206-215-2581 | |
John Steele Mullen, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 515 Minor Ave, Suite 200, Seattle, WA 98104 Phone: 206-215-2580 Fax: 206-215-2581 | |
Jeffrey M Mccracken, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 747 Broadway, Seattle, WA 98122 Phone: 206-386-2043 Fax: 206-386-2508 | |
Dr. Carol Collins, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 272 Health Sciences, 1959 Ne Pacific St, Seattle, WA 98195 Phone: 206-616-3294 | |
Dr. Daniel Warren Smith, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 9709 3rd Ave Ne, Seattle, WA 98115 Phone: 206-860-4944 | |
Tristan Marriner Nicholson, MD, PHD Urology Medicare: Accepting Medicare Assignments Practice Location: 1959 Ne Pacific St, Seattle, WA 98195 Phone: 206-520-5000 |